4 results
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
This study is designed to demonstrate equal therapeutic effect of Myfortic® as compared to MMF in this patient group, thus improving therapeutic efficacy.
There is need for evidence-based and reproducible data comparing the safety, longevity and patient satisfaction propensity of the various HA soft tissue filler products. In a survey among 67 Dutch cosmetic physicians in 2014, the Dutch National…
To assess the safety, tolerability, pharmacodynamics and efficacy of two DLQ02 topical formulations in patients with plaque psoriasis. To assess systemic exposure of CsA and F6H8 after topical application.